Prediction of metabolic syndrome among postmenopausal Ghanaian women using obesity and atherogenic markers

Lipids in Health and Disease

Lawrence Owusu¹  Faustina O Mensah²  James Osei-Yeboah³  Michael Adu-Frimpong²  Fareed K N Arthur² 

[1] Department of Medical Biochemistry and Molecular Biology, Dalian Medical University, 116044, 9 Western Section, Lvshun South Street, Lvshunkou District, Dalian City, P.R. China;Department of Biochemistry and Biotechnology, College of Science, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana;Department of Medical Laboratory Technology, College of Health, Kintampo, Ghana

关键词: Postmenopausal and premenopausal women;    Insulin resistance;    Abdominal adiposity;    Metabolic syndrome;   

Others  :  1160233
DOI  :  10.1186/1476-511X-11-101

 received in 2012-06-07, accepted in 2012-07-24,  发布年份 2012

【 摘 要 】

Background

Metabolic syndrome (MetS) is an important health problem which puts individuals at risk for cardiovascular diseases and type 2 diabetes as well as obesity-related cancers such as colon and renal cell in men, and endometrial and oesophageal in women.

Objective

This study was aimed at examining how obesity indicators and related determinants influence metabolic syndrome, and how the factors can be used to predict the syndrome and its cut-offs in postmenopausal Ghanaian women.

Methods

Two hundred and fifty (250) Ghanaian subjects were involved in the study with one hundred and forty-three (143) being premenopausal women and one hundred and seven (107) postmenopausal women. The influence of traditional metabolic risk factors including high blood pressure, dyslipidemia and glucose intolerance on obesity and atherogenic indices i.e. body mass index (BMI), waist circumference (WC), waist-to-hip ratio (WHR), Waist-to-thigh ratio (WTR), waist-to-height ratio (WHtR), high density lipoprotein cholesterol to total cholesterol ratio (HDL-C/TC), high density lipoprotein cholesterol to low density lipoprotein ratio (HDL-C/LDL-C) and triglyceride to high density lipoprotein cholesterol ratio (TG/HDL-C) were identified according to the Harmonization (H_MS) criterion.

Results

The predominant anthropometric marker that significantly influence metabolic risk factors among the pre- and postmenopausal women was waist-to-hip ratio (premenopausal: p- 0.004, 0.026 and 0.002 for systolic blood pressure (SBP), fasting blood glucose (FBG) and HDL-C; postmenopausal: p-0.012, 0.048, 0.007 and 0.0061 for diastolic blood pressure (DBP), FBG, triglyceride (TG) and high density lipoprotein cholesterol (HDL-C) respectively). Using the receiver operating characteristic (ROC) analysis, the area under the curve for WC, WHR, TG/HDL-C and HDL-C/TC among postmenopausal women were estimated at 0.6, 0.6, 0.8 and 0.8 respectively. The appropriate cut-off values for WC, WHR, TG/HDL-C and HDL-C/TC that predicted the presence of metabolic syndrome were 80.5 cm, 0.84, 0.61 and 0.34 respectively.

Conclusion

The presence of metabolic syndrome among Ghanaian postmenopausal women can be predicted using WC, WHR, TG/HDL-C and HDL-C/TC.

【 授权许可】

   
2012 Arthur et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Koerner A, Kratzsch J, Kiess W: Adipocytokines: leptin-the classsical, resistin-the controversial, adiponectin- the promissing, and more to come. Best Pract Res Clin Endocrinol Metab 2005, 19:525-546.
• [2]Funahashi T, Matsuzawa Y, Kihara S: Adiponectin as a potential key player in metabolic syndrome. Insights into atherosclerosis, diabetes and cancer. Int Congr Ser 2004, 1262:368-371.
• [3]Fulom T, Tessier D, Carpentier A: The Metabolic syndrome. Patholog Biol 2006, 54:375-386.
• [4]Paszkowski T, Kłodnicka M: Hormonal Therapy of menopause. Menopause 2007, 2:106-109.
• [5]Berman D, Rodrigues L, Nicklas B: Racial disparities in metabolism, central obesity, and sex hormone-binding globulin in postmenopausal women. J Clin Endocrinol Metab 2001, 86:97-103.
• [6]Poehlman E, Toth M, Gardner A: Changes in energy balance and body composition at menopause. A controlled londitudinal study. Ann Intern Med 1995, 123:673-675.
• [7]Arad Y, Newstein D, Cadet F: Association of multiple risk factors and insulin resistance with increased prevalence of asymptomatic coronary artery disease by an electron-beam computed tomographic study. Arterioscler Thromb Vasc Biol 2001, 2l:2051-2058.
• [8]Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, Taskinen M, Groop L: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24:683-689.
• [9]O’Donnell C, Elosua R: Cardiovascular risk factors. Insights from Framingham Heart Study. Rev Esp Cardiol 2008, 61:299-310.
• [10]Dayspring T: Cardiovascular disease: a comprehensive primer for clinicians. Menopause Management 2002, 11:1-9.
• [11]Igweh J, Nwagha I, Okaro J: The Effects of Menopause on the Serum Lipid Profile of Normal Females of South East Nigeria. Nigerian Journal Physiological Sciences 2005, 20:48-53.
• [12]Fleiss JL, Tytun A, Ury HK: Biometrics. 1980, 36:343-346.
• [13]Van Belle G: Statistical Rule of Thumb. second edition. New York: Wiley Interscience; 2008.
• [14]Neto J, Figueredo E, Barbosa J, Barbosa F, Costa G, Nina V, Nina R: Metabolic Syndrome and Menopause: Cross-sectional Study in Gynaecology Clinic. Universidade Federal do Maranhao 2010, Sep, 95(3):339-345.
• [15]Friedewald W, Levy R, Fredriskson D: Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma without use of the Preparative Ultra-Centrifuge. Clin Chem 1972, 18:499-502.
• [16]Trinder P: Determination of blood glucose using an oxidase peroxidase system with a non- carcinogenic chromogen. J Clin Pathol 1969, 22:158-161.
• [17]Vaidya R, Pandey S, Srinivas M, Nabar N: Metabolic syndrome: History synonyms and definition(s) Ed. Parihar M, Published by IMS Education Committee, Mumbai. IMS Digest 2011, 1:2-5.
• [18]Alberti K, Eckel R, Grundy S, Zimmet P, Cleeman J, Donato K: Harmonizing the metabolic syndrome: A joint interim statement of the international Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International association for the Study of Obesity. Circulation 2009, 120:1640-1645.
• [19]Hanley J, McNeil B: The meaning and use of the area under a Receiver Operating Characteristic (ROC) curve. Radiology 1982, 143:29-36.
• [20]Bonferroni CE: Il calcolo delle assicurazioni su gruppi di teste. In Studi in Onore del Professore Salvatore Ortu Carboni.Rome: Italy; 1935.
• [21]Ding Q, Hayashi T, Zhang X: Risks of CHD identified by Different Criteria of Metabolic Syndrome and Related Changes of Adipocytokines In Elderly Postmenopausal Women. J Diabetes Complications 2007, 21:315-319.
• [22]Lobo R: Metabolic syndrome after menopause and the role of hormones. Maturitas 2008, 60:10-18.
• [23]Shi H, Cleqq D: Sex differences in the regulation of body weight. Physiol Behav 2009, 97:199-204.
• [24]Pascot A, Despres J, Letnieux I: Contribution of visceral obesity to the deterioration of the metabolic risk profile in men with impaired glucose tolerance. Diabetologia 2000, 43:1126-1135.
• [25]Hamdy O, Porramatikul S, Al-Ozairi E: Metabolic Obesity: The Paradox Between Visceral and Subcutaneous Fat. Current Diabetes Reviews 2006, 2:1-7.
• [26]Després J: Abdominal obesity as important component of insulinresistance syndrome. Nutrition l993, 9:452-459.
• [27]Walton C, Lees B, Crook D, Godsland I, Stevenson I: Relationships between insulin metabolism, serum lipid profile, body fat distributionand blood pressure in healthy men. Atherosclerosis 1995, 118:35-43.
• [28]Kahn B, Flier I: Obesity arid insulin resistance. J Clin Invest 2000, 106:473-481.
• [29]Bergman R, Mittleman S: Central role of the adipocyte in insulin resistance. J Basic Clin Physiol Pharmacol 1998, 9:205-221.
• [30]Yokota T, Oritani K, Takahashi I: Adiponectin, a new member of the family of soluble defense collagens, negatively regulated the growth of myelomonocytic progenitors and the functions of macrophage. Blood Press 2000, 96:1723-1732.
• [31]Ruan X, Jin J, Hua L, Wang J, Liu S: The Prevalence of Metabolic Syndrome in Chinese Postmenopausal Women and the Optimum Body Composition Indices to Predict It. Menopause: The Journal of the North American Menopause Society 2010, 17:566-570.
• [32]Alberti K, Zimmet P, Shaw J: Metabolic Syndrome: a new world-wide definition: a consensus statement from the International Diabetes Federation. Diabet Med 2006, 23:469-480.
• [33]Alberti K, Eckel R, Grundy S, Zimmet P, Cleeman J, Donato K, Fruchart J-C, James W, Loria C, Smith SJ: Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120:1640-1645.
• [34]Okosun I, Rotimi C, Forrester T, Fraser H, Osotimehin B, Muna W, Cooper R: Predictive value of abdominal obesity cut-off points for hypertension in blacks from west African and Caribbean island nations. Int J Obes Relat Metab Disord 2000, 24:180-186.
• [35]Liu C-S, Hsu H-S, Li C-I, Jan C-I, Li T-C, Lin W-Y, Lin T, Chen Y-C, Lee C-C, Lin C-C: Central obesity and atherogenic dyslipidemia in metabolic syndrome are associated with increased risk for colorectal adenoma in a Chinese population. BMC Gastroenterol 2011, 10:51.
• [36]WHO: Obesity: prevention and managing the global epidemic, Report of a WHO consultation on obesity, WHO/NUT/NCD/98.1. Geneva: WHO; 1998.
• [37]World, Health, Organization: Obesity: Preventing and managing the global epidemic. In In Report of a WHO Consultation of obesity. Geneva: World Health Organization; 1998:1-1-9950.
• [38]Swets J: Measuring the accuracy of diagnostic systems. Science 1988, 240:1285-1293.
• [39]Rashid S, Uffelman K, Lewis G: The mechanism of HDL lowering in hypertriglyceridemic, insulin-resistant states. J Diabetes Complications 2002, 16:24-28.
• [40]Pascot A, Lemieux I, Prud’homme D, Tremblay A, Nadeau A, Couillard C, Bergeron J, Lamarche B, Despre´s J: Reduced HDL particle size as an additional feature of the atherogenic dyslipidemia of abdominal obesity. J Lipid Res 2001, 42:2007-2014.
• [41]Lemieux I, Pascot A, Prud’homme D, Alme´ras N, Bogaty P, Nadeau A, Bergeron J, Despre´s J: Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol 2001, 21:961-967.
• [42]Ross R, Freeman J, Hudson R, Janssen I: Abdominal obesity, muscle composition, and insulin resistance in premenopausal women. J Clin Endocrinol Metab 2002, 87:5044-5051.
• [43]Mertens I, Van der Planken M, Corthouts B, Van Gaal L: Is visceral adipose tissue a determinant of von Willebrand factor in overweight and obese premenopausal women? Metabolism 2006, 55:650-655.
• [44]Nieves D, Cnop M, Retzlaff B, Walden C, Brunzell J, Knopp R, Kahn S: The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat. Diabetes 2003, 52:172-179.
• [45]Flegal K, Carroll M, Ogden C, Johnson C: Prevalence and trends in Obesity among US Adults, 1999–2000. Jama 2002, 288:1723-1727.
• [46]Snijder M, Dekker J, Visser M, Bouter L, Stehouwer C, Kostense P, Yudkin J, Heine R, Nijpels G, Seidell J: Association of Hip and Thigh Circumferences Independent of Waist Circumference with the Incidence of Type 2 Diabetes: the Horn Study. Am J Clin Nutr 2003, 77:1192-1197.
• [47]Ryan A, Nicklas B, Berman D: Racial differences in insulin resistance and mid-thigh fat deposition in postmenopausal women. Obes Res 2002, 10:336-344.
• [48]Ghana Statistical Service, and, Macro, International, Inc: Preliminary Results. Maryland: Claverton; 2008. 2009